Christopher Horan, an officer at Artiva Biotherapeutics, has executed a sale of company stock valued at $63,072. This transaction was reported in accordance with regulatory requirements for insider trading. The details of the sale, including the number of shares sold and the price per share, have not been disclosed in the announcement. Artiva Biotherapeutics is a company focused on developing innovative therapies for cancer treatment.
Don't miss out on breaking stories and in-depth articles.
